Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres

Ana L. Keppke, Riad Salem, Denise Reddy, Jie Huang, Jianhua Jin, Andrew Christian Larson, Frank H Miller*

*Corresponding author for this work

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

OBJECTIVE. Yttrium-90 radioembolization is an emerging therapy for unresectable hepatocellular carcinoma (HCC). Although therapeutic response based on size has been evaluated in numerous studies, necrosis has been used as a criterion of response in only a few studies. The purpose of our study was to describe the imaging features of HCC after 90Y treatment and to compare size criteria (World Health Organization [WHO] and Response Evaluation Criteria in Solid Tumors [RECIST]) with necrosis criteria and combined criteria (RECIST and necrosis) for assessment of response. MATERIALS AND METHODS. CT images of 42 patients with 76 90Y-treated HCC lesions were analyzed. We used four response criteria: WHO size, RECIST size, necrosis, and combined criteria (RECIST and necrosis). Imaging features of treated lesions included both nodular and peripheral rim enhancement. Survival was assessed with the Kaplan-Meier method. RESULTS. The response rate was 23% according to RECIST criteria, 26% according to WHO criteria, 57% according to necrosis criteria, and 59% according to combined criteria. Response according to necrosis and combined criteria was detected earlier than response according to size criteria alone. Ten responding lesions initially increased in size. After therapy, enhancing peripheral nodules increased in size in 10 lesions, decreased in size in two lesions, and disappeared in two lesions. Twenty-one of 25 lesions with thin rim enhancement after 90Y administration responded to treatment. The median survival times were 660 and 236 days for Okuda stage I and Okuda stage II disease, respectively. CONCLUSION. Use of combined size and necrosis criteria may lead to more accurate assessment of response to 90Y therapy than use of size criteria alone. Imaging features after 90Y treatment, including size, necrosis, peripheral enhancing nodules, and thin rim enhancement, are described.

Original languageEnglish (US)
Pages (from-to)768-775
Number of pages8
JournalAmerican Journal of Roentgenology
Volume188
Issue number3
DOIs
StatePublished - Mar 1 2007

Fingerprint

Yttrium
Microspheres
Hepatocellular Carcinoma
Necrosis
Therapeutics
Survival
Response Evaluation Criteria in Solid Tumors

Keywords

  • Abdominal imaging
  • Brachytherapy
  • CT
  • Hepatocellular carcinoma
  • Interventional radiology
  • Liver
  • Oncologic imaging
  • Radioembolization
  • Yttrium-90

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Keppke, Ana L. ; Salem, Riad ; Reddy, Denise ; Huang, Jie ; Jin, Jianhua ; Larson, Andrew Christian ; Miller, Frank H. / Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. In: American Journal of Roentgenology. 2007 ; Vol. 188, No. 3. pp. 768-775.
@article{43b90cc94c3d41a49cf5627ed8ea9fc7,
title = "Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres",
abstract = "OBJECTIVE. Yttrium-90 radioembolization is an emerging therapy for unresectable hepatocellular carcinoma (HCC). Although therapeutic response based on size has been evaluated in numerous studies, necrosis has been used as a criterion of response in only a few studies. The purpose of our study was to describe the imaging features of HCC after 90Y treatment and to compare size criteria (World Health Organization [WHO] and Response Evaluation Criteria in Solid Tumors [RECIST]) with necrosis criteria and combined criteria (RECIST and necrosis) for assessment of response. MATERIALS AND METHODS. CT images of 42 patients with 76 90Y-treated HCC lesions were analyzed. We used four response criteria: WHO size, RECIST size, necrosis, and combined criteria (RECIST and necrosis). Imaging features of treated lesions included both nodular and peripheral rim enhancement. Survival was assessed with the Kaplan-Meier method. RESULTS. The response rate was 23{\%} according to RECIST criteria, 26{\%} according to WHO criteria, 57{\%} according to necrosis criteria, and 59{\%} according to combined criteria. Response according to necrosis and combined criteria was detected earlier than response according to size criteria alone. Ten responding lesions initially increased in size. After therapy, enhancing peripheral nodules increased in size in 10 lesions, decreased in size in two lesions, and disappeared in two lesions. Twenty-one of 25 lesions with thin rim enhancement after 90Y administration responded to treatment. The median survival times were 660 and 236 days for Okuda stage I and Okuda stage II disease, respectively. CONCLUSION. Use of combined size and necrosis criteria may lead to more accurate assessment of response to 90Y therapy than use of size criteria alone. Imaging features after 90Y treatment, including size, necrosis, peripheral enhancing nodules, and thin rim enhancement, are described.",
keywords = "Abdominal imaging, Brachytherapy, CT, Hepatocellular carcinoma, Interventional radiology, Liver, Oncologic imaging, Radioembolization, Yttrium-90",
author = "Keppke, {Ana L.} and Riad Salem and Denise Reddy and Jie Huang and Jianhua Jin and Larson, {Andrew Christian} and Miller, {Frank H}",
year = "2007",
month = "3",
day = "1",
doi = "10.2214/AJR.06.0706",
language = "English (US)",
volume = "188",
pages = "768--775",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "3",

}

Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. / Keppke, Ana L.; Salem, Riad; Reddy, Denise; Huang, Jie; Jin, Jianhua; Larson, Andrew Christian; Miller, Frank H.

In: American Journal of Roentgenology, Vol. 188, No. 3, 01.03.2007, p. 768-775.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres

AU - Keppke, Ana L.

AU - Salem, Riad

AU - Reddy, Denise

AU - Huang, Jie

AU - Jin, Jianhua

AU - Larson, Andrew Christian

AU - Miller, Frank H

PY - 2007/3/1

Y1 - 2007/3/1

N2 - OBJECTIVE. Yttrium-90 radioembolization is an emerging therapy for unresectable hepatocellular carcinoma (HCC). Although therapeutic response based on size has been evaluated in numerous studies, necrosis has been used as a criterion of response in only a few studies. The purpose of our study was to describe the imaging features of HCC after 90Y treatment and to compare size criteria (World Health Organization [WHO] and Response Evaluation Criteria in Solid Tumors [RECIST]) with necrosis criteria and combined criteria (RECIST and necrosis) for assessment of response. MATERIALS AND METHODS. CT images of 42 patients with 76 90Y-treated HCC lesions were analyzed. We used four response criteria: WHO size, RECIST size, necrosis, and combined criteria (RECIST and necrosis). Imaging features of treated lesions included both nodular and peripheral rim enhancement. Survival was assessed with the Kaplan-Meier method. RESULTS. The response rate was 23% according to RECIST criteria, 26% according to WHO criteria, 57% according to necrosis criteria, and 59% according to combined criteria. Response according to necrosis and combined criteria was detected earlier than response according to size criteria alone. Ten responding lesions initially increased in size. After therapy, enhancing peripheral nodules increased in size in 10 lesions, decreased in size in two lesions, and disappeared in two lesions. Twenty-one of 25 lesions with thin rim enhancement after 90Y administration responded to treatment. The median survival times were 660 and 236 days for Okuda stage I and Okuda stage II disease, respectively. CONCLUSION. Use of combined size and necrosis criteria may lead to more accurate assessment of response to 90Y therapy than use of size criteria alone. Imaging features after 90Y treatment, including size, necrosis, peripheral enhancing nodules, and thin rim enhancement, are described.

AB - OBJECTIVE. Yttrium-90 radioembolization is an emerging therapy for unresectable hepatocellular carcinoma (HCC). Although therapeutic response based on size has been evaluated in numerous studies, necrosis has been used as a criterion of response in only a few studies. The purpose of our study was to describe the imaging features of HCC after 90Y treatment and to compare size criteria (World Health Organization [WHO] and Response Evaluation Criteria in Solid Tumors [RECIST]) with necrosis criteria and combined criteria (RECIST and necrosis) for assessment of response. MATERIALS AND METHODS. CT images of 42 patients with 76 90Y-treated HCC lesions were analyzed. We used four response criteria: WHO size, RECIST size, necrosis, and combined criteria (RECIST and necrosis). Imaging features of treated lesions included both nodular and peripheral rim enhancement. Survival was assessed with the Kaplan-Meier method. RESULTS. The response rate was 23% according to RECIST criteria, 26% according to WHO criteria, 57% according to necrosis criteria, and 59% according to combined criteria. Response according to necrosis and combined criteria was detected earlier than response according to size criteria alone. Ten responding lesions initially increased in size. After therapy, enhancing peripheral nodules increased in size in 10 lesions, decreased in size in two lesions, and disappeared in two lesions. Twenty-one of 25 lesions with thin rim enhancement after 90Y administration responded to treatment. The median survival times were 660 and 236 days for Okuda stage I and Okuda stage II disease, respectively. CONCLUSION. Use of combined size and necrosis criteria may lead to more accurate assessment of response to 90Y therapy than use of size criteria alone. Imaging features after 90Y treatment, including size, necrosis, peripheral enhancing nodules, and thin rim enhancement, are described.

KW - Abdominal imaging

KW - Brachytherapy

KW - CT

KW - Hepatocellular carcinoma

KW - Interventional radiology

KW - Liver

KW - Oncologic imaging

KW - Radioembolization

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=33847200442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847200442&partnerID=8YFLogxK

U2 - 10.2214/AJR.06.0706

DO - 10.2214/AJR.06.0706

M3 - Article

C2 - 17312067

AN - SCOPUS:33847200442

VL - 188

SP - 768

EP - 775

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 3

ER -